These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18077485)

  • 41. A change in treatment from etanercept to infliximab was effective to control scleritis in a patient with rheumatoid arthritis.
    Sassa Y; Kawano Y; Yamana T; Mashima T; Ishibashi T
    Acta Ophthalmol; 2012 Mar; 90(2):e161-2. PubMed ID: 21470384
    [No Abstract]   [Full Text] [Related]  

  • 42. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate.
    Mease P; Strand V; Shalamberidze L; Dimic A; Raskina T; Xu LA; Liu Y; Smith J
    Ann Rheum Dis; 2012 Jul; 71(7):1183-9. PubMed ID: 22328739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis.
    Hoekstra M; van de Laar MA; Bernelot Moens HJ; Kruijsen MW; Haagsma CJ
    J Rheumatol; 2003 Nov; 30(11):2325-9. PubMed ID: 14677172
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents].
    Schnabel A; Gross WL
    Dtsch Med Wochenschr; 2003 Jan; 128(4):147-9. PubMed ID: 12589584
    [No Abstract]   [Full Text] [Related]  

  • 45. [Combination therapy for rheumatoid arthritis].
    Sibilia J
    Ann Med Interne (Paris); 2002 Feb; 153(1):41-52. PubMed ID: 11994689
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rituximab (MabThera) therapy and safety management. Clinical tool guide.
    Pham T; Fautrel B; Gottenberg JE; Goupille P; Hachulla E; Masson C; Morel J; Mouthon L; Saraux A; Schaeverbeke T; Wendling D; Mariette X; Sibilia ;
    Joint Bone Spine; 2008 Jun; 75 Suppl 1():S1-99. PubMed ID: 18708020
    [No Abstract]   [Full Text] [Related]  

  • 47. [Recent topics on new biological agents for treatment of rheumatoid arthritis].
    Saito K; Tanaka Y
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2418-23. PubMed ID: 19149039
    [No Abstract]   [Full Text] [Related]  

  • 48. Does gastrointestinal adverse drug reaction influence therapeutic effect in the treatment of rheumatoid arthritis?
    Jiang M; Zhao J; Lu A; Zha Q; He Y
    J Altern Complement Med; 2010 Feb; 16(2):143-4. PubMed ID: 20132037
    [No Abstract]   [Full Text] [Related]  

  • 49. Biological therapy for rheumatoid arthritis: where are we now?
    Horton SC; Emery P
    Br J Hosp Med (Lond); 2012 Jan; 73(1):12-8. PubMed ID: 22241404
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ulcerative colitis during CTLA-4Ig therapy in a patient with rheumatoid arthritis.
    Amezcua-Guerra LM; Hernández-Martínez B; Pineda C; Bojalil R
    Gut; 2006 Jul; 55(7):1059-60. PubMed ID: 16766771
    [No Abstract]   [Full Text] [Related]  

  • 51. Accelerated nodulosis immediately after initiating weekly low dose methotrexate for rheumatoid arthritis.
    Jun JB; Koh HK; Bae SC; Yoo DH; Kim SY
    Clin Exp Rheumatol; 1999; 17(1):127. PubMed ID: 10084052
    [No Abstract]   [Full Text] [Related]  

  • 52. N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis?
    Pincus T; Huizinga TW; Yazici Y
    J Rheumatol; 2007 Feb; 34(2):250-2. PubMed ID: 17304647
    [No Abstract]   [Full Text] [Related]  

  • 53. Summaries for patients: tofacitinib for the treatment of rheumatoid arthritis.
    Ann Intern Med; 2013 Aug; 159(4):I-26. PubMed ID: 24026272
    [No Abstract]   [Full Text] [Related]  

  • 54. A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks.
    den Uyl D; ter Wee M; Boers M; Kerstens P; Voskuyl A; Nurmohamed M; Raterman H; van Schaardenburg D; van Dillen N; Dijkmans B; Lems W
    Ann Rheum Dis; 2014 Jun; 73(6):1071-8. PubMed ID: 23606682
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ups and downs in the treatment strategies of rheumatoid arthritis.
    Schipper LG; van Riel PL
    Rheumatology (Oxford); 2011 May; 50(5):818-20. PubMed ID: 20663813
    [No Abstract]   [Full Text] [Related]  

  • 56. Early rheumatoid arthritis: combination therapy with disease-modifying antirheumatic drugs and low-dose glucocorticoids?
    Kirwan J
    Nat Clin Pract Rheumatol; 2006 Apr; 2(4):182-3. PubMed ID: 16932680
    [No Abstract]   [Full Text] [Related]  

  • 57. Disease-modifying antirheumatic drugs.
    Ryan L; Brooks P
    Curr Opin Rheumatol; 1999 May; 11(3):161-6. PubMed ID: 10328573
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New and promising treatments for rheumatoid arthritis.
    Looney RJ; Stohl W
    Am J Orthop (Belle Mead NJ); 2007 Jul; 36(7 Suppl):18-23. PubMed ID: 17694190
    [No Abstract]   [Full Text] [Related]  

  • 59. Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial.
    Rantalaiho V; Kautiainen H; Korpela M; Puolakka K; Blåfield H; Ilva K; Hannonen P; Leirisalo-Repo M; Möttönen T;
    Ann Rheum Dis; 2014 Apr; 73(4):788-90. PubMed ID: 24297374
    [No Abstract]   [Full Text] [Related]  

  • 60. Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis.
    Kremer JM
    Rheum Dis Clin North Am; 2004 May; 30(2):381-91, viii. PubMed ID: 15172047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.